Dabrafenib 50 mg ,75 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 50 mg ,75 mg

Reference Brands: Tafinlar (USA/EU)

Category: Oncology Cancer Care

Dabrafenib is a Oncology Cancer Care product available as Capsules in strengths 50 mg ,75 mg. It corresponds to the reference brand Tafinlar (USA/EU). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Dabrafenib is a targeted anticancer medication used for the treatment of cancers that carry specific BRAF gene mutations, particularly the BRAF V600E mutation. It works as a BRAF kinase inhibitor, blocking the abnormal B-Raf protein that drives uncontrolled cell growth and tumor development in mutation-positive cancers. By inhibiting this signaling pathway, dabrafenib helps slow or stop the growth of cancer cells.

It is used as a single agent for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and is also widely used in combination with the MEK inhibitor trametinib for broader mutation-positive cancers. Combination therapy is approved for indications including metastatic melanoma, metastatic non-small cell lung cancer, anaplastic thyroid cancer, and certain other unresectable or metastatic solid tumors with BRAF V600E mutation. Treatment selection is based on confirmed molecular testing. Dabrafenib is marketed under the brand name Tafinlar and is prescribed under oncology specialist supervision, with regular monitoring to manage safety and treatment response. It represents an important precision therapy option in mutation-driven cancer care.